University cracks top 100 in US patent tally

Comments (0) News

OMAHA & LINCOLN, Nebraska (June 22, 2021)—For the fourth consecutive year, the University of Nebraska system is ranked among the world’s top 100 institutions for securing U.S. patents.

A newly released report from the National Academy of Inventors and Intellectual Property Owners Association lists the NU system at No. 77. The ranking reflects the 38 patents that the U.S. Patent and Trademark Office granted in 2020 to the University’s technology transfer offices: UNeMed and her sister office NUtech Ventures in Lincoln. UNeMed is the technology transfer office for UNMC and UNO

“It’s incredibly gratifying to see Nebraska stand alongside world leaders of innovation and discovery,” said UNeMed president and CEO, Michael Dixon, PhD “But I’m even more excited about the fact that 75% of the US patents in our portfolio that issued last year have been licensed to companies for continued development and commercialization. That’s huge, and that’s the ultimate goal: Giving every innovation an opportunity to become a product that helps people.”

Patents allow UNeMed and NUtech Ventures to work with faculty, staff and students to bring research and innovations in areas like biotechnology, agriculture, healthcare, engineering and others to the marketplace. The results are new startup companies, jobs and university-licensed products that grow the economy and improve quality of life.

“The University of Nebraska Medical Center continues to grow basic science, translational and front line clinical research and discovery,” said Jeffrey P. Gold, M.D., chancellor at UNMC and UNO. “These dedicated faculty, staff and students continually develop new prevention strategies, diagnostics and treatments that improve the human condition and at the same time contribute to significant economic development. These activities are core to our mission of strengthening the economy and true excellence of our academic medical center.”

Patents from the University of Nebraska Medical Center include a surgical device that could dramatically improve the success rate for patients suffering from kidney disease and failure. For such patients, mere survival requires regular dialysis treatments, the success of which often rests on the outcome of a surgical procedure to create an AV or arteriovenous fistula.

A surgeon creates an AV fistula by connecting a vein, usually in the arm, with a nearby artery. The increased blood flow from the artery forces the vein to enlarge into a suitable portal for dialysis machine. However, AV fistulas are notoriously fickle, and fail to mature about half the time. UNMC’s patented device, invented by surgeon Marius Florescu, MD, is an implant that promotes more reliable and effective fistula maturation.

Last year, the University of Nebraska was ranked No. 65 for the number of patents secured in 2019. Nebraska ranked No. 79 in 2018 and No. 70 in 2017.

Read article

Three UNMC startups selected for Invest Midwest

Comments (0) News

Dong Wang, PhD

OMAHA, Nebraska (April 27, 2021)—Three Nebraska startup companies formed on the back of innovations developed at the University of Nebraska Medical Center were among a select group of presentations at the most recent Invest Midwest Venture Capital Forum.

The virtual conference spanned two days in late April, and featured more than 40 startup companies based on university technologies.

The goal of the forum was to help early-stage companies attract additional investment and support for further research and development of their products, particularly for university-based innovations.

The Nebraska startups selected to participate in the event were Ensign Pharmaceuticals, Global Laparoscopic Solutions and Intuitool.

Ensign Pharmaceuticals is a startup created by inventor and UNMC chemist Dong Wang, PhD, who developed a drug delivery platform called ProGel.

A liquid at lower temperatures, ProGel transforms into a gel-like substance as it reaches body temperature. As a result, the gel is then more likely to linger in the affected area, concentrating the pharmaceutical payload exactly where it needs to be.

Ensign Pharmaceutical’s initial product is a novel therapeutic prodrug for the most common cause of disability in the adult population: osteoarthritis pain.

The prodrug incorporates a potent steroid, dexamethasone, into the formulation. While effective for pain relief, the benefit of dexamethasone is unfortunately short-lived, usually lasting only a few days. However, when formulated with ProGel, dexamethasone has the potential to remain active much longer, potentially providing relief for months.

In addition to providing a more sustained and stable local release of medication, the hydrogel also has the benefit of limiting potential harmful side effects, including weight gain, increased blood sugar, insomnia and osteoporosis.

This device under development at Global Laparoscopic Solutions could make minimally invasive procedures more accessible and affordable throughout the world.

This device under development at Global Laparoscopic Solutions could make minimally invasive procedures more accessible and affordable throughout the world.

Any number of pharmaceuticals can combine with ProGel for localized and sustained delivery of a variety of therapeutic agents. For example, ProGel could help treat other musculoskeletal disorders such as chronic back pain, tendonitis, bursitis, fracture repair, spinal fusion, and periodontal bone regeneration. It may also serve as a depot for sustained drug delivery in a broad spectrum of disorders, including hormone therapy for high-risk pregnancy, and localized chemotherapy.

Global Laparoscopic Solutions is a startup company based on innovations from UNMC surgeon Chandra Are, MD.

The technology at GLS is an elegant solution to the lack of laparoscopic surgical options throughout the world. Essentially, the device transforms any standard operating room into a minimally invasive surgical suite. While providing access to the furthest corners of the globe, the innovation also simplifies minimally invasive procedures, and at more affordable prices.

Intuitool is also built on a laparoscopic surgical solution. It features an ergonomic design that enables better performance from the surgeons who wield it.

Pictured is an early prototype of the Intuitool.

An early prototype of the Intuitool.

Read article

Webinar will help researchers secure military support

Comments (0) News

OMAHA, Nebraska (June 9, 2021)—A free virtual seminar will explore the U.S. Army’s work with universities and businesses on biomedical innovations and discoveries that have potential for military applications, including therapeutics, vaccines, diagnostics, devices and information technology.

Sponsored by UNMC’s Vice Chancellor for Research and UNeMed, the seminar will be held via Microsoft Teams on Thursday, June 24 at noon. Anyone can join the one-hour event through this link or by dialing in at 402-797-7499. The phone conference ID is 591-474-296.

Barry Datlof, Chief of Business Development and Commercialization at the Office of Medical Technology Transfer in the U.S. Army Medical Research & Development Command, will deliver the presentation, “Advance your technology with the DOD.”

Michael Dixon

Dr. Dixon

Datlof’s remarks will also include tips on how to navigate and identify potential funding opportunities and write effective Cooperative Research and Development Agreements.

UNeMed CEO and President Michael Dixon, PhD, will emcee the event.

Direct any questions to research@unmc.edu.

Read article

Applications open for small business, research funding opportunities

Comments (0) News

LINCOLN, Nebraska (June 9, 2021)—Applications for Nebraska’s Business Innovation Act programs are now open.

Administered by the Nebraska Department of Economic Development, the Business Innovation Act offers several programs aimed toward helping small businesses, startup companies and entrepreneurs. The funding programs include prototype grants, research and development grants, SBIR/STTR grants, and seed investment opportunities.

There is no specific deadline for any program application, however applications will be accepted until all funding is exhausted. Program administrators will review applications about every two weeks. Several “how-to” guides on the Nebraska.gov website address most questions about the programs and the application process. The how-to guides can be found at: https://opportunity.nebraska.gov/amplifund/#bia-award.

Prototype Grant

Nebraska’s prototype grant program is a matching grant meant to offset some costs related to product development. Applications must include a business plan, evidence of matching funds, and any other relevant information. The award cap is $150,000, but most funded applications are in the $50,000 range.

Academic R&D Grant

Nebraska’s Academic R&D grant program helps businesses that financially support research and development at a Nebraska university or college, or businesses that have licensed intellectual property created at a Nebraska college or university. The funding is intended to support the additional research and development necessary to successfully commercialize innovations and new technologies. Application must include a budget, scope of work, description of the business, and a draft agreement with the participating college or university. The award cap is $100,000 for Phase I projects and $400,000 for Phase II projects.

Small Business Innovation Research/Small Business Tech Transfer Grants

Nebraska’s SBIR/STTR program is a matching grant that provides financial assistance to Nebraska businesses that are applying for (Phase 0) or have received a Federal SBIR or STTR grant (Phase I or Phase II). The Phase 0 program helps with costs to respond to a federal solicitation and does not require a match. The Phase I and Phase II programs can match a federal SBIR/STTR grant at 65 percent of the federal award, up to $100,000.

Seed Investment

Nebraska’s seed investment program allows the state to invest up to $500,000 in a Nebraska business to help commercialize a product or process. Any state investment must be matched 100 percent with non-state money. Invest Nebraska oversees this program, conducting all due diligence, setting terms, and ultimately holding any investment made.

Read article

Tech Transfer Boot Camp will return, applications now open for 2021

Comments (0) News

OMAHA, Neb. (June 1, 2021)—The 2021 Technology Transfer Boot Camp is scheduled to return as an in-person event on Aug. 16-20, UNeMed announced today.

Tech Transfer Boot Camp aims at scientists and students interested in what it takes to commercialize a new invention or discovery. The week-long event can also jump-start an alternate career in science as a technology transfer professional.

The program helps scientists gain a wide range of skills and experience that match their scientific knowledge and training.

Boot Camp focuses on several key areas relevant to a successful career in technology transfer, including:

  • Invention evaluation
  • Intellectual property law
  • Marketing and commercialization
  • Contract negotiation

UNeMed’s Tech Transfer Boot Camp dives deeper than simple lectures. Topics wills be explored with hands-on activities meant to teach, correct and reinforce new skills and abilities.

Anyone within the University of Nebraska system is encouraged to apply and participate free of charge, but space is limited. People who aren’t affiliated with the University of Nebraska are also welcome, but will be charged $200 upon acceptance.

Applications are open through Friday, July 30, and will be reviewed in the order they are received until all spaces are filled.

Use the embedded form below or apply here: https://docs.google.com/forms/d/e/1FAIpQLSf5j7HSF6qfRnqS6VUlp1L5QvrcXIM1asPq36fxlnGp1mkrAQ/viewform?usp=sf_link.

More information about the application process and requirements can be found at https://www.unemed.com/about-us/join-our-team#bootcamp.

Read article

Free webinar offered for prepping SBIR/STTR proposals

Comments (0) News

SHARPhub logoCHELSEA, Michigan (April 29, 2021)—SHARPhub is hosting a free webinar next week about SBIR/STTR proposal prep for National Institutes of Health grant funding.

Small Business Innovation Research and Small Business Technology Transfer programs are federal research and development grant funds administered by a dozen government agencies, including the National Science Foundation, NASA and the Department of Defense, to name a few. Each year, the top two programs award more than $3 billion to small businesses.

Open to the public, the webinar will cover the differences between SBIR and STTR, how to navigate the NIH’s SBIR website to research awarded projects, registrations, etc.  The webinar will also cover how to prepare an SBIR proposal, and how to avoid common pitfalls.

The webinar is scheduled for Thursday, May 6 at 8:30 a.m. until 1 p.m., central standard time. Event organizers ask that those interested in this free event to please register at: https://zoom.us/webinar/register/7816195323372/WN_3kADZV-UR-aMZa4DI4MCIw

SHARPhub provides this opportunity at no charge as a part of its mission to coach and provide opportunities and resources that would help commercialize life-science innovations in the Midwest. SHARPhub is the technology transfer hub for the Sustainable Heartland Accelerator Regional Partnership, which is a collaboration between BBC Entrepreneurial Training & Consulting and the five-state Midwestern region.

The planned agenda for the webinar:

  • Quick SBIR/STTR Overview; NIH Essentials (including navigating sbir.nih.gov; NIH RePORTER; registrations; review criteria)
  • Proposal Prep 1: Specific Aims, Research Strategy; using SA to contact NIH
  • Proposal Prep 2: Budgets, Biosketches, Facilities, and Resources
  • Questions; next steps for SHARPhub program

 

Read article

Grants available for new technology development

Comments (0) News

Learn about the Nebraska Business Development Act, how to gain access to ‘valley of death’ funding

A panel of experts will break down the several benefits and uses of key provisions of Nebraska’s Business Innovation Act for academic researchers and faculty.

Michael Dixon

Michael Dixon, PhD

“We’re advising all University inventors to sit in on this one,” said Michael Dixon, PhD, President and CEO at UNeMed, the technology transfer and commercialization office for UNMC and UNO. “I think they’ll find that the state is quite interested in helping to support start-up companies developing University technology, as well as established Nebraska companies that are doing research and development with the University.  This webinar will help researchers understand how to gain access to this critical “valley of death” funding.”

The “valley of death” refers to the funding gap into which most academic innovations fall. The vast majority of academic discoveries and innovations are initially supported through generous federal grant programs. However, most of those discoveries falter or stagnate because few programs provide the necessary and significant amounts of additional resources needed for further development. Among the few “gap” or “valley of death” programs is Nebraska’s Business Innovation Act of 2011.

The Business Innovation Act established a raft of financial and technical supports intended to promote both startup growth and University-Industry research collaborations within the state. Nebraska’s Department of Economic Development—which manages most of those funding programs—will host the upcoming free webinar. Their funding programs help pay for research and development; support collaborations with Nebraska businesses; match federal funding from the SBIR/STTR programs; fund prototype development; and help commercialize new innovations.

The webinar is planned for Thursday, April 29 at 1:30 p.m. The event is free, but registration with a university email address is required. Register online at: https://research.unl.edu/events/industryRelations_nuramp.php?EMSEventUUID=1462c807-4d8f-4015-b454-95b1b243d384.

Dr. Dixon will be among four panelists during the event. Business innovation consultants from the DED, Ben Kuspa and Nisha Avey, will also be on the panel. They will be joined by Ryan Anderson, the Director of Industry Relations at the University of Nebraska-Lincoln. The emcee and Q&A facilitator will be Sara Bennett, Associate Director of the Nebraska Business Development Center.

Planned areas of discussion include:

  • Business Innovation Act grant and investment programs
  • Nebraska Academic Research Program
  • SBIR/STTR matching program
  • Upcoming program changes for 2022
  • How to utilize the program
  • NU Connections can help your business

Read article

UNeMed seeking intern candidates

Comments (0) News

OMAHA, Nebraska (March 31, 2021)—UNeMed Corporation, the technology transfer and commercialization office for the University of Nebraska Medical Center and University of Nebraska Omaha, is now seeking qualified candidates for its paid internship program.

UNeMed’s interns gain hands-on training, mentorship and all the tools needed to launch a successful career in the technology transfer or biotechnology industry.

All interns work closely with experienced UNeMed staff to help biomedical inventions developed at UNMC and UNO move beyond the laboratory and into the marketplace. UNeMed interns will gain valuable, first-hand experience in a wide range of interdisciplinary, technology transfer-related activities, including:

  • Invention evaluations
  • Patent and copyright law
  • Contract negotiation
  • Startup business formation
  • Technology marketing

The ideal candidate will:

  • Be actively working towards or hold an advanced degree in a scientific field
  • Have the ability to comprehend complicated scientific and technical information
  • Have excellent research, analytical and writing skills
  • Strong written and oral communication skills
  • Be an independent thinker who is self-motivated and can take initiative while still contributing to a dynamic, fast-paced team environment
  • Be able to work with the diverse range of personalities often found among elite academic researchers and biomedical industry executives
  • Have the ability work on several projects at one time

UNeMed interns will be expected to:

  • Help evaluate new invention submissions
  • Develop technical marketing summaries
  • Conduct market analysis research
  • Promote UNeMed and UNMC innovations to local, regional and national companies
  • Manage marketing campaigns
  • Identify potential licensees
  • Develop communication strategies to promote UNMC and UNO technologies

To apply, submit a résumé or CV with a letter expressing interest to UNeMed@unmc.edu, with “UNeMed Internship” in the subject line. UNeMed will accept applications until the position is filled.

Read article

UNMC joins WIPO Re:Search consortium for tropical diseases

Comments (0) News

March 29, 2021 (OMAHA, Nebraska)—The University of Nebraska Medical Center and its technology transfer and commercialization arm, UNeMed, are now one of 153 listed world-wide organizations that are sharing research and resources to fight tropical diseases in developing nations.

“We are excited to be part of this group,” said Jennifer Larsen, MD, Vice Chancellor for Research at UNMC,” as it provides new strategies and options for funding for our faculty’s work on therapeutics for diseases that have a significant global impact but are often off the radar for many pharmaceutical companies.”

The World Intellectual Property Organization and BIO Ventures for Global Health partnered in 2011 to create the WIPO Re:Search consortium. Their stated mission is “Accelerate the discovery and development of technologies for neglected tropical diseases, malaria and tuberculosis by sharing intellectual property with the global health research community, catalyzing and fostering global health collaborations, and contributing to capacity-building in developing countries.”

Among the noteworthy member institutions are Emory University, the Pasteur Institute, MIT, NIH, Stanford, the US Patent and Trademark Office and dozens of other major American universities.

Jonathon Vennerstrom, PhD

Jonathon Vennerstrom, PhD

“University researchers like Jonathan Vennerstrom and his team create new knowledge and deeper understanding of complex diseases like this all the time,” UNeMed president and CEO Michael Dixon, PhD, said. “This consortium is just another example of how committed the University is to putting that knowledge to work, and getting these life-saving treatments into the hands of the people who need it most.”

Jonathan Vennerstrom, PhD, a medicinal chemist in UNMC’s College of Pharmacy, has already made significant contributions to the global fight against malaria. Through his work with Medicines for Malaria Venture, he and his team created a new malaria drug that was approved for use in India in 2012 and has shown potential as a one-dose cure for malaria. That work was recognized with the prestigious 2019 American Chemical Society Award for Creative Invention. In addition, a panel of world health experts selected it in 2015 as one of 30 high-impact innovations that can save lives and transform global health within 15 years.

The WIPO Re:Search consortium will give UNMC researchers access to resources that go beyond combined knowledge and discovery. It also includes access to potential industrial partners like GlaxoSmithKline, Johnson & Johnson, Merck, Novartis and Pfizer, to name a few.

Read article

1-Check COVID screener app will expand in new partnership

Comments (0) News

OMAHA, Nebraska (March 8, 2021)—Amid a burgeoning pandemic more than a year ago, Apple, Inc. partnered with the University of Nebraska on a critical challenge.

“They asked if we had the capacity to co-develop an app to allow anyone to input symptoms, and then learn next steps,” said Harnoor Singh, the Director of Student Development for the Walter Scott, Jr. Scholarship Program at UNO. “And they said, ‘Respond by 4 p.m. today.'”

Challenge accepted.

There was a problem, however: Apple’s deadline to submit a finished app was less than two weeks.

At the time, there was only one other such app on the market: The one produced by software engineers at Apple, no less.

The 1-Check COVID app would become the second…and in record time.

Under normal circumstances, it might take the better part of a year to develop an app. Add another two months for Apple to vet and approve the app.

But a Nebraska team of students, faculty and clinicians developed 1-Check in just 12 days. Then Apple turned around its approval for inclusion in the App Store in a neck-breaking four hours. (The app is also available for Android devices and as a web application that should work with any browser.)

Now, just a few months and more than 30 versions later, the app continues to guide decisions for the state’s largest employer, and will expand its range and reach in a new partnership with an east coast developer, Civilience.

“It was very much a whirlwind from the start,” said Michael Wadman, MD, chairman of UNMC’s Department of Emergency Medicine.

Wadman and his team—Department of Emergency Medicine Executive Vice Chair, Wesley Zeger, DO, and Thang Nguyen, a nurse practitioner in Emergency Medicine with no less than 50 inventions to his credit—cobbled together the algorithms in a flurry of marathon sessions that spanned two days. They continue to update the algorithms at frequent intervals.

Spurred by Chancellor Jeffrey Gold, MD, the plan was to build an app that could help people track symptoms and other circumstances. That information could then offer clues about the likelihood that the user might be sick. More importantly, the app would help provide our public health leaders with community syndromic surveillance and provide the user with the next appropriate steps regarding testing, vaccination, quarantine, etc.

“The app isn’t making a determination that you’re COVID-positive,” said Rod Markin, MD, UNMC’s Vice Chancellor for Business Development and Director of UNeTech. “It’s making a determination if you need to seek input from your healthcare provider.”

Making that determination is the series of algorithms the Wadman team helped create, which are based on their large body of clinical experience with infectious diseases. To the user, the algorithms look like a set of simple questions that ask about symptoms and potential exposures to the novel coronavirus responsible for the pandemic, SARS-CoV-2.

Inside the app, however, it is a little more complex. The app weighs all those answers to score the user’s risk of infection as either high, moderate or low.

The actual coding of the app itself—the design, interface and function—was built by Singh’s Scott Scholar undergraduate students, Grayson Stanton, who majors in Computer Engineering and Mathematics, and two Computer Science majors in Keegan Brown and Carly Cameron.

“We had brand new developers, 18-, 19-, 20-years-old,” said Singh. “One day they’re developing an app, the next day their delivering a report to the governor or executives at Apple.”

He added later: “It’s awesome what you can accomplish when given high-achieving students and real-world problems to solve using a human-centered approach.”

Nebraska’s ability to produce one potential solution to the problem of the day helped the University’s technology transfer and commercialization office in Omaha, UNeMed, attract Civilience as a commercial partner. A virtual company with employees throughout the East Coast, Civilience is a situational awareness-signaling platform providing health security as a lifestyle. The initial focus is on identifying “transmissibility” or infectiousness as a way to help people safely integrate the business of life in a new post-pandemic reality.

“Our partnership with Civilience will allow us to expand the reach and impact of the 1-Check Covid technology and add value to a health security platform that already has users scattered across the globe,” said UNeMed President and CEO, Michael Dixon.

Civilience will roll the app into its portfolio while updating accuracy and expanding functions. The app will enable users to understand at a glance the regional risk of infection in their local area and the risk of infection at a venue such as at an event or store. The app will also help people understand on a personal level their risks both of catching or passing infection to others.

UNMC and Nebraska Medicine will continue to collaborate with Civilience as clinicians learn more about the virus; the disease and conditions it creates; how the infection progresses; and what impacts might be created from additional factors, such as vaccinations or previous COVID-19 infections. To help with that collaboration, Civilience plans to headquarter in Omaha once the pandemic improves.

“Our name combines ‘civil defense’ and ‘resilience,'” said Civilience CEO and founder Rina Singh. “We empower people and their communities by helping them to take informed and incentivized action in the face of challenges, natural or manmade.”

Civilience also expects to build the app into a screener that goes beyond COVID-19. Future plans include screeners for seasonal flu and other emergency-level infections.

Read article

MidWest Drug Development Conference sets initial slate of participants, more to come

Comments (0) News

OMAHA, Nebraska (February 22, 2021)—With a little more than eight months before the MidWest Drug Development Conference returns from its one-year hiatus, nine universities have already announced their intention to participate in the two-day event.

The preliminary list of participating institutions:

  • Kansas State University
  • Mayo Clinic
  • Ohio State University
  • Purdue University
  • University of Kansas
  • University of Minnesota
  • University of Nebraska Medical Center
  • University of Oklahoma
  • WARF (University of Wisconsin)

A handful of spots remain open for additional participants, which are expected to fill out in the coming weeks. Previous participants have included Cincinnati Children’s Hospital, University of Iowa, University of Kentucky and University of Missouri, to name a few.

Each participating institution will highlight two or three of their new therapeutic developments in short, 10-minute presentations. Specific information about those presentations will be announced later this summer.

The conference is tentatively scheduled for October 4-5.

“Hopefully, as the vaccine rollout continues, we’ll reach a point very soon when large, in-person events like this will be safe again,” event organizer and director of licensing at UNeMed, Matt Boehm, said earlier this year.

UNeMed is the conference’s primary organizer and sponsor, and the technology transfer office for all Omaha campuses of the University of Nebraska.

The 2020 MidWest Drug Development Conference was canceled due to the COVID-19 pandemic.

In 2019, a dozen universities presented 42 new, drug-related technologies. The audience was a collection of pharmaceutical companies, biotech companies, venture capital groups and other potential partners who could help further develop those new technologies.

In 2019, the second year of the conference, 111 people attended, including representatives from 30 companies and investment groups. About 240 one-on-one partnering meetings were scheduled over the two-day conference.

Due to the remaining uncertainty for 2021, however, registrations will remain closed for the time being.

Those interested to learn more about the concern may subscribe for any updates as they happen. They may also reach out to conference organizers to learn more about the conference, speakers, sponsorships opportunities, or other details.

Read article

Several inventors to be honored as Distinguished Scientists today

Comments (0) News

OMAHA, Neb. (Feb. 23, 2021)—Several key inventors on more than 50 innovations will be honored today at 4:30 p.m. when the University of Nebraska Medical Center presents its virtual Distinguished Scientists Awards ceremony.

Jingwei Xie, PhD

“We weren’t surprised to see some of our top inventors listed as Distinguished Scientists,” said Matt Boehm, PhD, UNeMed’s Director of Licensing. “Excellent research creates opportunities to develop discoveries into products that improve healthcare.”

While each of the 2020 Distinguished Scientists have made a remarkable impact on research at UNMC, they are also driving past presentations and publications to make sure their research and discoveries make an impact on society.

For example, three in particular stand out as inventors listed on at least 43 inventions: Channabasavaiah Gurumurthy, PhD; Hanjun Wang, MD; and Jingwei Xie, PhD.

Channabasavaiah Gurumurthy, PhD

Dr. Xie, an assistant professor in the Department of Surgery and a leader in the Regenerative Medicine program, has more than two dozen inventions to his credit, many specializing in nanofiber-based materials that promote wound healing and tissue growth.

Previously, Dr. Xie was presented the New Investigator award in 2017, the same year UNeMed named his “Nanofiber Sponges for Hemostasis” as the Most Promising New Invention of the Year.

He was also presented the 2019 Chancellor Emeritus Harold M. Maurer, MD, and Beverly Maurer Scientific Achievement Award, and was honored as one of UNeMed’s “Innovators of the Year” in 2020.

Dr. Gurumurthy was also among UNeMed’s 2020 “Innovators of the Year.”

Hanjun Wang, MD

Hanjun Wang, MD

A professor in the Department of Pharmacology and Experimental Neuroscience and the director of the Mouse Genome Engineering Core Facility, Dr. Gurumurthy has 10 inventions during his tenure at UNMC. Most of his inventions involve improvements to the CRISPR gene-editing tool, one of which is license to an industrial partner.

Dr. Wang is an associate professor in the Department of Cellular & Integrative Physiology, and has two inventions that are currently licensed to commercialization partners, including a midsized biotech and a recently created startup company.

His work on methods for treating cardiovascular diseases has led to more than a dozen new inventions; and more than $1 million in industrial sponsored research that will help further develop his discoveries.

Dr. Wang was previously presented a UNMC New Investigator Award in 2015.

The portal to watch the ceremony, and a complete list of all UNMC’s 2020 honorees—including the Scientist Laureate, the highest honor UNMC bestows to researchers—is available on UNMC’s website: https://www.unmc.edu/research/distinguished-scientists/index.html.

Read article

UNMC startup secures $1.93 million for its new arthritis treatment, ProGel

Comments (0) News

OMAHA, Nebraska (February 1, 2021)—A startup company founded by UNMC College of Pharmacy scientist Dong Wang, PhD, landed a fast-track Small Business Innovation and Research grant of nearly $2 million for a potentially transformative new treatment for arthritis.

The initial Phase I National Institute on Drug Abuse award of $250,000 supported a successful proof of concept study. The Phase I grant was supported with an additional $100,000 in matching funds from the Nebraska Department of Economic Development. The $1.68 million Phase II funding was approved on Jan. 5, 2021. It will support a series of pre-clinical studies that are designed to open the door to filing an investigational new drug application with the FDA.

Dr. Wang

“This will prepare us for talking to the FDA about the design and implementation of a clinical trial to test the safety and effectiveness of the new drug,” Dr. Wang said, adding later: “We’re really lucky because the rheumatology and orthopedic programs at UNMC are world class, and have established the Nebraska Arthritis Outcomes Research Center, which has the personnel and expertise to conduct the clinical trials. The campus will be an ideal place to initiate the clinical studies.”

Dr. Wang founded Ensign Pharmaceutical on a novel formulation called ProGel, which is an injectable liquid. After ProGel is injected, it transforms into a gel-like substance as it reaches body temperature. The gel is then more likely to linger in the affected area, concentrating the pharmaceutical payload exactly where it needs to be.

Any number of pharmaceuticals can be combined with ProGel, making it a “platform technology.” Platform technologies like ProGel can be used for localized and sustained delivery of a variety of therapeutic agents to treat a broad spectrum of clinical conditions.

Ensign’s first product will incorporate a potent steroid, dexamethasone, into the ProGel formulation. The Phase II study will identify the optimal formulation, and evaluate its long-term efficacy in the treatment of arthritic joint pain.

Dexamethasone is a synthetic version of an anti-inflammatory steroid normally produced by the human adrenal gland. It is a common treatment for lupus, asthma and many other inflammatory diseases, and has gained recent notoriety for its potential in fighting the COVID-19 pandemic. When injected into a joint, dexamethasone provides temporary relief of debilitating pain and swelling caused by osteoarthritis, a chronic condition that slowly erodes the protective cartilage at the end of bones.

“It’s important to note that there is no known cure for osteoarthritis,” said Ensign’s Chief Medical Officer, Steven Goldring, MD, former Chief of Rheumatology at Beth Israel Deaconess Medical Center in Boston and Professor of Medicine at Harvard Medical School. “Unfortunately, the best we can do today is to manage the pain and inflammation.”

While effective for pain relief, the benefit of dexamethasone is unfortunately short-lived, usually lasting only a few days. However, when formulated with Dr. Wang’s ProGel, dexamethasone has the potential to remain active much longer, potentially providing relief for months.

“In mouse models of osteoarthritis, ProGel has shown effective pain relief for at least four months,” Dr. Wang said, “but a mouse is very, very different than a human being…These new experiments will help us to better predict how it may work in humans, and to optimize the drug design to provide similar sustained pain relief in humans.”

The hydrogel allows a slow release of the payload—dexamethasone, in this case—while being retained at the injection site. In addition to providing a more sustained and stable local release of medication, the hydrogel also has the benefit of limiting potential harmful side effects, including weight gain, increased blood sugar, insomnia and osteoporosis.

Ensign Pharmaceutical and ProGel also won the 2020 Business Innovation Live Pitch competition in Phoenix during the Orthopaedic Research Society’s annual meeting.

“Something like that is great because it shows us that we’re not the only ones who are excited about this technology and this company,” said Ensign’s CEO Brian Beck.

Read article

Dixon will speak at online symposium

Comments (0) News

Online forum will focus on entrepreneurial opportunities with U.S. Defense

OMAHA, Nebraska (January 29, 2020)—A free online symposium will walk through various local entrepreneurial opportunities in the national defense market.

Michael Dixon

Dr. Dixon

The symposium is ideal for early-stage ventures and startup companies that have potential for the military or national security. The forum will explore the nature of defense venture development and a federal grant programs dedicated to small businesses and early-stage technologies.

Among the planned speakers is UNeMed President and CEO, Michael Dixon, PhD. His 10-minute presentation is set for 10:15 a.m.

Other presentations will provide overviews of other local resources that include the Nebraska Business Development Center, startup accelerator NMotion, and the University of Nebraska at Omaha’s Center for Innovation, Entrepreneurship and Franchising.

Scheduled for Friday, Feb. 5, the Entrepreneurial Symposium will focus on the National Security Innovation Network’s acceleration program for business startups. More specifically, the accelerator seeks new, creative solutions to problems facing the Department of Defense and U.S. armed services members.

The symposium is scheduled to begin at 9 a.m. with an overview of the National Security Innovation Network, a program within the Department of Defense that intends to help connect universities and entrepreneurs on projects that can meet the needs of national defense and security.

The online conference is expect to conclude at 1:30 p.m.

Registration is free and open to all. To register and learn more about the event go to https://www.eventbrite.com/e/entrepreneurial-symposium-tickets-136480778683.

Read article

UNeTech to help with new postdoc grant program

Comments (0) News

OMAHA, Neb. (January 19, 2021)—A new funding opportunity from the National Cancer Institute aims squarely at helping post-doctoral researchers advance university innovations into new startup companies.

Called the Small Business Transition Grant for Early Career Scientists, it is part of the Small Business Technology Transfer and Small Business Innovation Research programs, or STTR/SBIR for short. The stated purpose of the new grant is to help postdocs transition from academia to an entrepreneurial enterprise.

Joe Runge

An advantage for UNMC cancer researchers is the added resource of UNeTech, the University’s startup accelerator and incubator institute. Among UNeTech’s critical strengths are its resources dedicated to support university entrepreneurs. In particular, those resources include assistance with writing the grant proposal, company formation and mentoring.

“The transition grant opportunity is proof that NIH really gets the challenges faced by new graduates to start entrepreneurial careers,” UNeTech’s Associate Director Joe Runge said. “UNeTech exists to take advantage of programs like this, and I am so excited to help brilliant scientists use it to start amazing companies.”

Proposals for the transition grant program must fit into at least one of the following categories:

  1. Therapeutics and preventative agents
  2. Imaging technologies, interventional devices and in vivo diagnostics
  3. In vitro and ex vivo diagnostics and prognostics

A transition grant would begin as a Phase I STTR, which would allow the postdoc to continue working at the university while completing proof of concept studies. Those studies could then be used to propel the technology into a small business startup, and potentially transition to a Phase II SBIR award. Phase II SBIR grants are often two-year awards that build on the research and development of a Phase I STTR.

The transition grant would also qualify for Nebraska’s SBIR/STTR grant-matching program through the Department of Economic Development.

Letters of intent for the new transition grant are due 30 days before the application. The application deadline is March 10, 2021. Anyone interested in pursuing a transition grant should contact UNeTech Associate Director, Joe Runge, at 559-1181 or hrunge@unmc.ecu.

Read article

Murari-Kanti headlines Bio Nebraska event

Comments (0) News

OMAHA, Neb. (January 14, 2021)—Catherine Murari-Kanti, PhD, a licensing specialist at UNeMed, is the featured speaker for a Nebraska Women in STEM event planned for Thursday, Feb. 4.

Dr. Murari-Kanti’s presentation is titled, “Women and Entrepreneurship: Can we do it? Yes we can!”

Catherine Murari-Kanti

Dr. Murari-Kanti

The one-hour virtual event is planned to start at 10:30 a.m. Tickets are $25, but free for students. To register and learn more, go to https://www.eventbrite.com/e/women-and-entrepreneurship-can-we-do-it-yes-we-can-tickets-136009027663.

She will discuss potential solutions for women entrepreneurs and the obstacles they face. She will also discuss her work in technology transfer and research commercialization, and lay out some of the entrepreneurial opportunities available through UNeMed and the wider Omaha community.

Bio Nebraska is hosting the event as a part of its Nebraska Women in STEM initiative, which is aimed at helping support and encourage women interested and specializing in scientific, technical, engineering and mathematical fields. Bio Nebraska is a trade organization aimed at helping grow the state’s “bio-ecosystem.”

Dr. Murari-Kanti holds a PhD in cancer research, and joined UNeMed in 2016. She evaluates new inventions for their commercial potential and helps establish intellectual property protections for new innovations and discoveries. She works closely with University innovators to help them push their inventions beyond the laboratory and into the market. She also has significant experience working within the entrepreneurial and startup community.

UNeMed is the technology transfer and commercialization office for the University of Nebraska Medical Center and the University of Nebraska at Omaha.

Read article